Lactobacillus GG in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers: A randomized, double-blind, placebo-controlled trial

Published:October 05, 2009DOI:https://doi.org/10.1016/j.clnu.2009.09.008

      Summary

      Background & aims

      The aim of our study was to investigate the role of Lactobacillus GG (LGG) in the prevention of gastrointestinal and respiratory tract infections in children who attend day care centers.

      Methods

      We conducted a randomized, double-blind, placebo-controlled trial in 281 children who attend day care centers. They were randomly allocated to receive LGG at a dose of 109 colony-forming units in 100 ml of a fermented milk product (LGG group, n=139) or placebo that was the same post-pasteurized fermented milk product without LGG (placebo group, n=142) during the 3-month intervention period.

      Results

      Compared to the placebo group, children in the LGG group had a significantly reduced risk of upper respiratory tract infections (RR 0.66, 95% CI 0.52 to 0.82, NNT 5, 95% CI 4 to 10), a reduced risk of respiratory tract infections lasting longer than 3 days (RR 0.57, 95% CI 0.41 to 0.78, NNT 5, 95% CI 4 to 11), and a significantly lower number of days with respiratory symptoms (p<0.001). There was no risk reduction in regard to lower respiratory tract infections (RR 0.82, 95% CI 0.24 to 2.76). Compared with the placebo group, children in the LGG group had no significant reduction in the risk of gastrointestinal infections (RR 0.63, 95% CI 0.38 to 1.06), vomiting episodes (RR 0.60, 95% CI 0.29 to 1.24), and diarrheal episodes (RR 0.63, 95% CI 0.35 to 1.11) as well as no reduction in the number of days with gastrointestinal symptoms (p=0.063).

      Conclusion

      LGG administration can be recommended as a valid measure for decreasing the risk of upper respiratory tract infections in children attending day care centers.

      Keywords

      Abbreviations:

      LGG (Lactobacillus GG), RR (relative risk), CI (95% confidence interval), NNT (number needed to treat)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Nutrition
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Lu N.
        • Samuels M.E.
        • Shi L.
        • Baker S.L.
        • Glover S.H.
        • Sanders J.M.
        Child day care risks of common infectious diseases revisited.
        Child Care Health Dev. 2004; 30: 361-368
        • Landis S.E.
        • Chang A.
        Child care options for ill children.
        Pediatrics. 1991; 88: 705-718
        • Carpenter E.S.
        Children's health care and the changing role of women.
        Med Care. 1980; 18: 1208-1218
        • Oberhelman R.A.
        • Gilman R.H.
        • Sheen P.
        • Taylor D.N.
        • Black R.E.
        • Cabrera L.
        • et al.
        A placebo-controlled trial of Lactobacillus GG to prevent diarrhea in undernourished Peruvian children.
        J Pediatr. 1999; 134: 15-20
        • de Vrese M.
        • Winkler P.
        • Rautenberg P.
        • Harder T.
        • Noah C.
        • Laue C.
        • et al.
        Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: a double blind, randomized, controlled trial.
        Clin Nutr. 2005; 24: 481-491
        • Kukkonen K.
        • Savilahti E.
        • Haahtela T.
        • Juntunen-Backman K.
        • Korpela R.
        • Poussa T.
        • et al.
        Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial.
        Pediatrics. 2008; 122: 8-12
        • Weizman Z.
        • Asli G.
        • Alsheikh A.
        Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents.
        Pediatrics. 2005; 115: 5-9
        • Hatakka K.
        • Savilahti E.
        • Ponka A.
        • Meurman J.H.
        • Poussa T.
        • Näse L.
        • et al.
        Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial.
        BMJ. 2001; 322: 1327-1331
        • Thibault H.
        • Aubert-Jacquin C.
        • Goulet O.
        Effects of long-term consumption of a fermented infant formula (with Bifidobacterium breve c50 and Streptococcus thermophilus 065) on acute diarrhea in healthy infants.
        J Pediatr Gastroenterol Nutr. 2004; 39: 147-152
        • Saavedra J.M.
        Use of probiotics in pediatrics: rationale, mechanisms of action, and practical aspects.
        Nutr Clin Pract. 2007; 22: 351-365
        • Isolauri E.
        • Sutas Y.
        • Kankaanpaa P.
        • Arvilommi H.
        • Salminen S.
        Probiotics: effects on immunity.
        Am J Clin Nutr. 2001; 73: 444S-450S
        • Chiang B.L.
        • Sheih Y.H.
        • Wang L.H.
        • Liao C.K.
        • Gill H.S.
        Enhancing immunity by dietary consumption of a probiotic lactic acid bacterium (Bifidobacterium lactis HN019): optimization and definition of cellular immune responses.
        Eur J Clin Nutr. 2000; 54: 849-855
        • Rinne M.
        • Kalliomaki M.
        • Arvilommi H.
        • Salminen S.
        • Isolauri E.
        Effect of probiotics and breastfeeding on the Bifidobacterium and Lactobacillus/enterococcus microbiota and humoral immune responses.
        J Pediatr. 2005; 147: 186-191
        • Viljanen M.
        • Kuitunen M.
        • Haahtela T.
        • Juntunen-Backman K.
        • Korpela R.
        • Savilahti E.
        Probiotic effects on faecal inflammatory markers and on faecal IgA in food allergic atopic eczema/dermatitis syndrome infants.
        Pediatr Allergy Immunol. 2005; 16: 65-71
        • Isolauri E.
        • Joensuu J.
        • Suomalainen H.
        • Luomala M.
        • Vesikari T.
        Improved immunogenicity of oral D x RRV reassortant rotavirus vaccine by Lactobacillus casei GG.
        Vaccine. 1995; 13: 310-312
        • Isolauri E.
        • Arvola T.
        • Sutas Y.
        • Moilanen E.
        • Salminen S.
        Probiotics in the management of atopic eczema.
        Clin Exp Allergy. 2000; 30: 1604-1610
        • Pessi T.
        • Sutas Y.
        • Hurme M.
        • Isolauri E.
        Interleukin-10 generation in atopic children following oral Lactobacillus rhamnosus GG.
        Clin Exp Allergy. 2000; 30: 1804-1808
        • Majamaa H.
        • Isolauri E.
        • Saxelin M.
        • Vesikari T.
        Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis.
        J Pediatr Gastroenterol Nutr. 1995; 20: 333-338
        • Moher D.
        • Schulz K.F.
        • Altman D.G.
        The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials.
        Lancet. 2001; 357: 1191-1194